Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivastigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 11/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 1/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivastigmine SCHEMBL25232361 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL29779663 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL3978590 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL29612619 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL30064255 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL13841811 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL29614698 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL1170429 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL6382107 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL6382629 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9583 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250333435-A1 | TIMOSAPONIN COMPOUNDS | GOLDPORP PHARMA LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250329454-A1 | DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS | CHASE THERAPEUTICS CORP (US) | 2025-10-23 | — | — | US | claimed |
| US-20250304565-A1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix Inc. (US) | 2025-10-02 | — | — | US | claimed |
| EP-3562483-B1 | NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250214984-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-03 | — | — | US | claimed |
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | claimed |
| US-20250134959-A1 | GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR NEURODEGENERATIVE OR NEUROLOGICAL DISEASES OR DISORDERS | PARTNER THERAPEUTICS, INC. | 2025-05-01 | — | — | US | claimed |
| CN-119896733-A | Compound, preparation method and medical application thereof | 百泰生物药业有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119790152-A | Treatment of neurological disorders using modulators of UNC13A gene transcripts | 奎里斯公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2003041563-A2 | NEUROTRANSMITTER BALANCE CHEMOTHERAPY | BE ABLE, LLC (US) | 2003-05-22 | — | — | WO | claimed |
| EP-1311511-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | Agouron Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020151591-A1 | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders | NEUROGEN CORPORATION | 2002-10-17 | — | — | US | claimed |
| US-20020091145-A1 | Behavior chemotherapy | EIG MARK H (US) | 2002-07-11 | — | — | US | claimed |
| US-20020065292-A1 | For use in therapy of neurodegenerative diseases and certain cancers | AGOURON PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | claimed |
| WO-2002032412-A2 | COMBINATION USE OF ACETYLCHOLINESTERASE INHIBITORS AND GABAA INVERSE AGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| WO-2002016365-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1998030243-A1 | ACETYLCHOLINESTERASE INHIBITORS IN COMBINATION WITH MUSCARINIC AGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | WARNER-LAMBERT COMPANY (US) | 1998-07-16 | — | — | WO | claimed |